News
TEVA
17.10
+1.79%
0.30
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
NASDAQ · 1d ago
Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease
Benzinga · 1d ago
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe ulcerative colitis and crohn's disease. The RELIEVE UCCD Phase 2b trial has completed early due to significant acceleration in patient recruitment. Teva and sanofi now anticipate having topline results for both UC and CD in Q4 2024.
Barchart · 2d ago
Piper Sandler Remains a Buy on Teva Pharmaceutical (TEVA)
TipRanks · 2d ago
Teva Pharmaceutical: Hold Rating Amidst Steady Quarter Performance and Market Uncertainties
TipRanks · 2d ago
Why Hims & Hers Heath Shares Are Surging Today
Hims & Hers Health Inc. Appointed former Novo Nordisk COO and President Kåre Schultz to its Board of Directors. Schultz was instrumental in establishing the company as a leader in diabetes care. Schultz brings extensive experience from his leadership roles at Lundbeck and Teva Pharmaceutical Industries.
Benzinga · 4d ago
Court weighs what US must prove in Regeneron kickback case
U.S. Department of Justice wants appeals court to overturn judge's ruling in kickback case against drugmaker. The Justice Department accused Regeneron Pharmaceuticals of using a charity to pay kickbacks to pay for drugs. The drugmaker denies the allegations. The government says the ruling makes it harder to hold companies accountable for paying kickbacks.
Reuters · 4d ago
Hims & Hers appoints former Novo Nordisk president to board
Seeking Alpha · 4d ago
Weekly Report: what happened at TEVA last week (0715-0719)?
Weekly Report · 4d ago
EFV, AER, TEVA, CCEP: Large Outflows Detected at ETF
NASDAQ · 07/19 15:02
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
NASDAQ · 07/19 12:56
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Pharmaceutical Industries Ltd. Announced results from its Phase 3 SPACE study. The study is evaluating the efficacy of Ajovy for the prevention of episodic migraine in children and adolescent patients aged 6-17. Ajovy achieved a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
Benzinga · 07/18 16:06
Teva meets main goal in trial for its migraine prevention in children and adolescents
Healthcare Teva meets main goal in trial for its migraine prevention in children and adolescents. The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment. Teva Pharmaceutical Industries Limited (TEVA) Stock.
Seeking Alpha · 07/18 12:57
Teva SPACE Pediatric Phase 3 Study Met Its Primary End Point For Efficacy With A Significantly Greater Reduction In Monthly Migraine Days Compared To Placebo; Efficacy Is Consistent With AJOVY Pivotal Phase 3 And Real-World Evidence Studies In Adults With No New Emergent Safety Signals Observed
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo. Efficacy is consistent with AJOVY's pivotal Phase 3 and Real-World Evidence studies in adults. Full data to be presented at a medical meeting later in 2024.
Benzinga · 07/18 12:36
BRIEF-Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine
Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine. The drug is being tested on children.
Reuters · 07/18 12:33
TEVA: SPACE PEDIATRIC PHASE 3 STUDY MET ITS PRIMARY END POINT
Reuters · 07/18 12:30
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Jim Cramer said Fortinet, Inc. Is not his favorite stock. He said Air Products and Chemicals is a better run company than Linde plc. Cramer recommended not selling Match Group, Inc (NASDAQ:MTCH) The "Mad Money" host said Costco is the best of the breed.
Benzinga · 07/17 12:55
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when put to work in innovation-driven businesses. If you have $200 ready to invest, the following three stocks stand out as no-brainer buys. Travel-and-hosting company Airbnb and generic drug developer Teva Pharmaceutical Industries are great buys. Teva is in the midst of a turnaround.
The Motley Fool · 07/17 09:21
Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Teva Pharmaceutical Indus has outperformed the market over the past 5 years by 3.91%. The company has an average annual return of 17.49%. If an investor bought $1000 of TEVA stock 5 years ago, it would be worth $2,176.36 today.
Benzinga · 07/16 16:03
MediWound Files Amendment To Settlement Agreement With Teva; Under Amendment, Co Will Prepay Teva $4M As Final Payment Due From Company Under Agreement; 50% Of Prepayment In Cash, 50% In Form Of Ordinary Shares Of Co To Be Issued By Co To Teva
Benzinga · 07/15 20:13
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.